African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

Abstract

Introduction: Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our model developed in Europeans (PHS46), showed reduced performance in men with African genetic ancestry. We used a cross-validated search to identify SNPs that might improve performance in this population.

Material and Methods: Anonymized genotypic data were obtained from the PRACTICAL consortium for 6,253 men with African genetic ancestry. Ten iterations of a ten-fold cross-validation search were conducted, to select SNPs that would be included in the final PHS46+African model. The coefficients of PHS46+African were estimated in a Cox proportional hazards framework using age at diagnosis as the dependent variable and PHS46, and selected SNPs as predictors. The performance of PHS46 and PHS46+African were compared using the same cross-validated approach.

Results: Three SNPs (rs76229939, rs74421890, and rs5013678) were selected for inclusion in PHS46+African. All three SNPs are located on chromosome 8q24. PHS46+African showed substantial improvements in all performance metrics measured, including a 75% increase in the relative hazard of those in the upper 20% compared to the bottom 20% (2.47 to 4.34) and a 20% reduction in the relative hazard of those in the bottom 20% compared to the middle 40% (0.65 to 0.53).

Conclusions: We identified three SNPs that substantially improved the association of PHS46 with age at diagnosis of prostate cancer in men with African genetic ancestry to levels comparable to Europeans and Asians. A strategy of building on established statistical models might benefit ancestral groups generally under-represented in genome-wide association studies.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Introduction

Polygenic models can provide personalized estimates of the risk of developing prostate cancer. In the context of survival analysis, these models can provide insight into age at diagnosis of prostate cancer, and thus could be used to guide decisions on whether and when to offer screening\(^1\). Studies of polygenic models have often included only individuals of European genetic ancestry, owing to greater availability of data from that population\(^2,3\). As a consequence, these models have been tailored to identify and estimate coefficients of genetic common variants for that particular population, while potentially missing variants that may hold value in other populations\(^2\). There is concern that using these European-focused models could actually exacerbate health disparities\(^2-4\).

As an example, our group recently published on the performance of a polygenic hazard score (PHS) originally developed using a European dataset, in a multi-ethnic dataset consisting of individuals of European, African, and Asian genetic ancestry\(^5\). The model (called here PHS46), includes 46 single nucleotide polymorphisms (SNPs) in its calculation and was strongly associated with age at diagnosis in all three genetic populations (p<10\(^{-16}\)). However, the hazard ratio for prostate cancer between individuals in the upper 20\(^{th}\) percentile to those in the lower 20\(^{th}\) percentile of PHS46 was approximately half as large for those with African genetic ancestry (2.6) as it was for those with European (5.6) or Asian (4.6) ancestry. A similar pattern was observed for clinically significant prostate cancer and for death from prostate cancer.

In the current study, we attempt to bridge the apparent gap in model performance of PHS46 for individuals with African genetic ancestry. To this end, we used a machine learning approach to systematically search for SNPs that add statistical value to a base model of PHS46 among African men (PHS46+African). By including PHS46 as a
covariate in our SNP search, we sought to identify those SNPs that may hold particular value for individuals with African genetic ancestry.

Material and Methods

Study dataset

We obtained genotype and phenotype data from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium for this study. Genotyping was performed using the OncoArray platform and had undergone quality assurance steps, as described previously. The genotypic ancestry of each individual was also determined previously. In total, the African dataset consisted of data from 6,253 men with African genotypic ancestry. Missing SNP calls were replaced with the mean of the genotyped data for that SNP in the African dataset. Individuals without prostate cancer were censored at age at last follow-up in the Cox proportional hazards models. All contributing studies were approved by the relevant ethics committees; written informed consent was obtained from the study participants.

The present analyses used de-identified data from the PRACTICAL consortium. Please refer to Table S1 for a description of the PRACTICAL study groups that contributed data towards this analysis. PHS46 risk score for each individual in the African dataset was estimated as the sum of SNP allele counts (X) multiplied by their respective coefficients (β):

$$PHS46 = \sum_{i=1}^{46} X_i \beta_i$$

SNP-scan

Training and testing sets were generated using 10 iterations of a 10-fold cross-validation structure resulting in 100 total permutations. For each permutation, a
multivariable logistic regression model using case/control status as the dependent variable was estimated using each genotyped SNP in turn, adjusting for PHS46 and four principal components based on genetic ancestry, determined previously. SNPs with p-values less than $1 \times 10^{-6}$ were considered for further analysis. In order of increasing p-value, each SNP was tested in a multiple Cox proportional hazards model, after adjusting for PHS46, four ancestral principal components, and previously selected SNPs. The Cox model in the SNP-scan used age at diagnosis of prostate cancer as the dependent variable. If the p-value of the coefficient of the tested SNP was less than $1 \times 10^{-6}$, it was considered for the final model in that permutation. SNPs that reached this p-value threshold in more than 50% of the permutations were selected to construct the PHS46+African model, consisting of PHS46 and the newly identified SNPs.

Comparing performance between PHS46 and PHS46+African

For each permutation of the previously described cross-validation structure, an PHS46+African Cox proportional hazards model was estimated in the training set using PHS46 and the selected SNPs as independent predictors. The PHS46+African risk score for each individual is then estimated using the corresponding PHS46 score, selected SNP allele counts ($Y$) and their respective coefficients ($\alpha$):

$$PHS46 + African = PHS46 + \sum_{j=1}^{SNPs} Y_j \alpha_j$$

The performance of the PHS46+African and PHS46 models was then determined in the cross-validation testing set, and the resulting hazard ratios (HR) were obtained, as previously described. For each model, the PHS risk scores within the cross-validation testing set are assigned to quantile groups identified using the corresponding training set control values. The hazard ratio between two quantile groups, such as those in the top 20% to those in the bottom 20%, is estimated as the exponential of the difference in
mean PHS values for each group. In this calculation, the PHS values are linearly scaled by a sample-weight correction factor, to account for case-control sampling\textsuperscript{1,5,10}. Three HR were calculated: HR80/20 (top 20% to bottom 20%), HR98/50 (top 2% to middle 40%) and HR20/50 (bottom 20% to middle 40%). The average HR across permutations for both PHS46+African and PHS46 are reported.

To allow for comparisons with previously published results, the performance metrics for PHS46 and PHS46+African were also estimated for age at diagnosis of clinically significant prostate cancer. When estimating performance for clinically significant prostate cancer, controls and non-clinically significant cancers were censored at age of last follow-up and age of diagnosis, respectively. The previously used criteria for clinically significant cancer were any of: Gleason score >=7, stage T3-T4, PSA concentration >= 10ng/mL, nodal metastasis, or distant metastasis\textsuperscript{1}. Paired t-tests were used to test for statistical significant differences ($\alpha = 0.05$) in HR between PHS46+African and PHS46.

Additionally, in each permutation, the performance of a Cox model consisting of PHS46 and SNPs that were considered in that permutation was also estimated. These results are provided within the Table S2 and provide performance estimates that are not prone to information leakage from training to testing set.

Characterization of PHS+African

Coefficients of the PHS46+African model, consisting of PHS46 and the SNPs selected in the SNP-scan, were estimated using 1000 bootstrapped samples of the African dataset.

Results

Individual and OncoArray characteristics
In total, there were 3,013 men with (cases) and 3,240 men without (controls) prostate cancer in the African dataset. The mean [95% CI] ages of cases and controls were 62.4 [62.1, 62.7] and 61.8 [61.4, 62.1] years respectively. The OncoArray genotypic data, after the quality assurance process, included 444,323 SNPs.

**Single Nucleotide Polymorphism (SNP)-scan**

Across the 100 permutations of the cross-validation iterations, a total of twelve SNPs were considered for final selection (Table S3). Three SNPs were selected in more than 50% of the permutations and included in the final PHS46+African model. By cross-referencing the chromosomal positions against dbSNP\(^1\), these variants were identified as rs76229939, rs74421890, and rs5013678. All 3 SNPs (Table 1) are located on chromosome 8q24, a region of the chromosome previously identified as containing common variants associated with prostate cancer\(^12,13\). An examination of the Pearson correlation coefficients (Table S4) showed little correlation, ranging from -0.05 to -0.07, among genotype data from the 3 SNPs in the African dataset.

Reference threshold (Table S5) and mean (Table S6) values for PHS46+African in the African dataset are presented in the Supplemental Data.

**Performance of PHS46+African**

Figure 1 demonstrates the difference in HRs between PHS46+African and PHS46 within the African dataset using age at diagnosis of any prostate cancer. Overall, we observed an improvement in all the metrics calculated: a 75% increase in HR98/50 from 2.10 to 3.67; a 79% increase in HR80/20 from 2.47 to 4.42; and a 23% decrease in HR20/50 from 0.65 to 0.51. We also observed improvements in all performance metrics when using age at diagnosis of clinically significant prostate cancer: 103% increase in HR98/50 from 1.91 to 3.88, 113% improvement in HR80/20 from 2.21 to 4.71, and 29%...
improvement in HR20/50 from 0.70 to 0.50. All observed changes in HR were statistically significant (p < 1x10^{-16}).

Discussion

Using a cross-validated search of a dataset made up entirely of men with African genetic ancestry, we were able to identify three SNPs that substantially improved the performance of PHS46 in this population to levels that are comparable to those observed in Europeans and Asians. The three SNPs, rs76229939, rs74421890, and rs5013678, are all located on chromosome 8q24 – a region of the genome where variants have been associated with prostate cancer in both the general population and specifically in men with African genetic ancestry\(^{13,14}\). Despite the relative proximity of the three SNPs on chromosome 8, their genetic data was not strongly correlated in our dataset, suggesting that each SNP provides non-redundant information for an individual’s genetic score.

Each of the three SNPs have been previously identified in the literature to be associated with prostate cancer: rs76229939 is an intron variant of the prostate-cancer-associated transcript 2 (PCAT2) gene, while rs74421890 and rs5013678 are both non-coding transcript variants of the prostate-cancer-associated non-coding RNA 1 (PRNCR1) gene. The minor allele frequencies of rs76229939 and rs74421890 in Europeans, as reported by dbSNP\(^{11}\), are approximately zero to three decimal places, which may explain why they were not selected in the original formulation of PHS46.

This study is not meant to be an exhaustive search for all possible SNPs that are associated with the age of diagnosis of prostate cancer in individuals with African genetic ancestry. Our study is also limited by the small number of available observations relative to those often found in many genome-wide association studies, which can have tens or hundreds of thousands of individuals. However, we were able to extract...
information that is likely robust by employing a cross-validated search for those SNPs
that specifically add value to the performance of PHS46, and not simply independently
associated with prostate cancer. We also note that no SNP score, including PHS46 and
PHS46+African, has been shown to discriminate men at risk of aggressive prostate
cancer from those at risk of indolent prostate cancer. Finally, the performance metrics
reported in this study may be biased by the leakage of information across cross-
validated folds of the data when identifying those SNPs to include in the final African-
PHS model. This bias is expected to be similar for all SNPs and should not have
influenced selection of the three SNPs included in the final model over those not
selected.

In conclusion, we identified three SNPs (rs76229939, rs74421890, and
rs5013678) that substantially improved the performance of PHS46 in a dataset of men
with African genetic ancestry. We believe that this strategy of building on established
models developed on large dataset could be applied to other groups that are generally
under-represented in genome-wide association studies. This strategy may further help to
bridge performance gaps in personalized genetic risk scores across populations.
References


Figure Legends

Figure 1. Comparison between PHS46 and PHS46+African. Mean hazard ratio metrics plotted for PHS46 and PHS46+African models in the African dataset.

Improvements were observed in all performance metrics investigated. Error bars represent 95% confidence interval.
Table 1. Characteristics of PHS46+African SNPs. RS-ID, chromosome and base-pair position (based on version 37), effect and reference alleles, bootstrap-estimated beta, and effect allele frequencies in Africans from 1000Genomes (referenced from dbSNP) of the three SNPs selected for addition to PHS46.

<table>
<thead>
<tr>
<th>RS number</th>
<th>Chromosome</th>
<th>Position</th>
<th>Effect</th>
<th>Ref</th>
<th>beta</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs76229939</td>
<td>8</td>
<td>128085394</td>
<td>G</td>
<td>A</td>
<td>0.441</td>
<td>4.8</td>
</tr>
<tr>
<td>rs74421890</td>
<td>8</td>
<td>128096183</td>
<td>A</td>
<td>G</td>
<td>0.415</td>
<td>4.1</td>
</tr>
<tr>
<td>rs5013678</td>
<td>8</td>
<td>128103979</td>
<td>G</td>
<td>A</td>
<td>-0.260</td>
<td>8.1</td>
</tr>
</tbody>
</table>
Supplemental Data Description

The Supplemental Data contains (1) six tables
Appendix A1. Data Availability Statement

The data used in this work were obtained from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium, Readers who are interested in accessing the data must first submit a proposal to the Data Access Committee. If the reader is not a member of the consortium, their concept form must be sponsored by a principal investigator (PI) of one of the PRACTICAL consortium member studies. If approved by the Data Access Committee, PIs within the consortium, each of whom retains ownership of their data submitted to the consortium, can then choose to participate in the specific proposal. In addition, portions of the data are available for request from dbGaP (database of Genotypes and Phenotypes) which is maintained by the National Center for Biotechnology Information (NCBI):


Anyone can apply to join the consortium. The eligibility requirements are listed here:

http://practical.icr.ac.uk/blog/?page_id=9. Joining the consortium would not guarantee access, as a proposal for access would still be submitted to the Data Access Committee, but there would be no need for a separate member sponsor. Readers may find information about application by using the contact information below:

Rosalind Eeles
Principal Investigator for PRACTICAL
Professor of Oncogenetics
Institute of Cancer Research (ICR)
Sutton, UK
Email: PRACTICAL@icr.ac.uk
URL: http://practical.icr.ac.uk
Tel: ++44 (0)20 8722 4094
Appendix A2. Funding sources for the PRACTICAL consortium

CRUK and PRACTICAL consortium

This work was supported by the Canadian Institutes of Health Research, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I].

This study would not have been possible without the contributions of the following: Coordination team, bioinformatician and genotyping centers: Genotyping at CCGE, Cambridge: Caroline Baines and Don Conroy
Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

This study would not have been possible without the contributions of the following: Per Hall (COGS); Douglas F. Easton, Paul Pharoah, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang (BCAC), Andrew Berchuck (OCAC), Rosalind A. Eeles, Douglas F. Easton, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Joe Dennis, Alison M. Dunning, Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissiere and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility

Additional funding and acknowledgments from studies in PRACTICAL:

Information of the PRACTICAL consortium can be found at http://practical.icr.ac.uk/

BioVU

The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center’s BioVU, which is supported by institutional funding and by the National Center for Research Resources, Grant UL1 RR024975-01 (which is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06).
CPDR
Uniformed Services University for the Health Sciences HU0001-10-2-0002 (PI: David G. McLeod, MD)

EPICAP
The EPICAP study was supported by grants from Ligue Nationale Contre le Cancer; Institut National du Cancer (INCa); Fondation ARC; Fondation de France; Agence Nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES); Ligue départementale du Val de Marne. The EPICAP study group would like to thank all urologists, Antoinette Anger and Hasina Randrianasolo (study monitors), Anne-Laure Astolfi, Coline Bernard, Oriane Noyer, Marie-Hélène De Campo, Sandrine Margaroline, Louise N'Diaye, Sabine Perrier-Bonnet (Clinical Research nurses)

KARUPROSTATE
The Karuprostate study was supported by the Frech National Health Directorate, the Association pour la Recherche sur le Cancer, la Ligue Nationale contre le Cancer, the French Agency for Environmental and Occupational Health Safety (ANSES) and by the Association pour la Recherche sur les Tumeurs de la Prostate. We would like to thank Séverine Ferdinand for valuable contributions to the study.

MOFFITT
The Moffitt group was supported by the US National Cancer Institute (R01CA128813, PI: J.Y. Park).

NMHS
Funding for the Nashville Men's Health Study (NMHS) was provided by the National Institutes of Health Grant numbers: RO1CA121060

PCaP
The North Carolina - Louisiana Prostate Cancer Project (PCaP) and the Health Care Access and Prostate Cancer Treatment in North Carolina (HCaP-NC) study are carried out as collaborative studies supported by the Department of Defense contract DAMD 17-
03-2-0052 and the American Cancer Society award RSGT-08-008-01-CPHPS, respectively.

The authors thank the staff, advisory committees and research subjects participating in the PCaP and HCaP-NC studies for their important contributions.

**PROtEuS**

PROtEuS was supported financially through grants from the Canadian Cancer Society [13149, 19500, 19864, 19865] and the Cancer Research Society, in partnership with the Ministère de l'enseignement supérieur, de la recherche, de la science et de la technologie du Québec, and the Fonds de la recherche du Québec - Santé. PROtEuS would like to thank its collaborators and research personnel, and the urologists involved in subjects recruitment. We also wish to acknowledge the special contribution made by Ann Hsing and Anand Chokkalingam to the conception of the genetic component of PROtEuS.

**SABOR**

The SABOR research is supported by NIH/NCI Early Detection Research Network, grant U01 CA086640-18. Also supported by the Cancer Center Support Grant to the Mays Cancer Center from the National Cancer Institute (US) P30 CA054174

**SCCS**

SCCS is funded by NIH grant R01 CA092447, and SCCS sample preparation was conducted at the Epidemiology Biospecimen Core Lab that is supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA68485). Data on SCCS cancer cases used in this publication were provided by the Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer Registry, 4815 W. Markham, Little Rock, AR 72205. The Arkansas Central Cancer Registry is fully funded by a grant from National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected by the Mississippi Cancer Registry which
participates in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi Cancer Registry.

SCPCS
SCPCS is funded by CDC grant S1135-19/19, and SCPCS sample preparation was conducted at the Epidemiology Biospecimen Core Lab that is supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA68485).

SFPCS
SFPCS was funded by California Cancer Research Fund grant 99-00527V-10182

SWOG-PCPT / SWOG-SELECT
PCPT and SELECT are funded by Public Health Service grants U10CA37429 and 5UM1CA182883 from the National Cancer Institute. The authors thank the site investigators and staff and, most importantly, the participants from PCPT who donated their time to this trial.

UKGPCS
UKGPCS would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. UKGPCS should also like to acknowledge the NCRN nurses, data managers and Consultants for their work in the UKGPCS study. UKGPCS would like to thank all urologists and other persons involved in the planning, coordination, and data collection of the study. KM and AL were in part supported from the NIHR Manchester Biomedical Research Centre

WUGS
WUGS would like to thank the following for funding support: The Anthony DeNovi Fund, the Donald C. McGraw Foundation, and the St. Louis Men’s Group Against Cancer.
Appendix A3 – Members of the PRACTICAL Consortium


¹Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA
²Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106-7219, USA
³Seidman Cancer Center, University Hospitals, Cleveland, OH 44106, USA.
⁴Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK
⁵The Institute of Cancer Research, London, SM2 5NG, UK
⁶Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
⁷University of Cambridge, Department of Clinical Neurosciences, Stroke Research Group, R3, Box 83, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK
⁸Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, 20892, USA
⁹Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171
John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK

University of Cambridge, Department of Oncology, Box 279, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK

Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX1 2JD, UK

Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK

Population Health Sciences, Bristol Medical School, University of Bristol, BS8 2PS, UK

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK

Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto ON M5G 2M9, Canada

Dept. of Surgery (Urology), University of Toronto, Canada

Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA

Department of Radiation Oncology and Department of Genetics and Genomic Sciences, Box 1236, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-5674, USA.

Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK

Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC 3004, Australia

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia

Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3168, Australia

Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, 15706, Spain.

Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, 15706, Spain.

Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain

ISGlobal, Barcelona, Spain
Department of Urology, University of Washington, 1959 NE Pacific Street, Box 356510, Seattle, WA 98195, USA
66Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany
67Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria
68Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2
69Division of Radiation Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2
70Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE-3000, Belgium
71Division of Cancer Sciences, Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Health Innovation Manchester, Univeristy of Manchester, M13 9WL
72Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS, 15706, Santiago de Compostela, Spain
73University of California San Diego, Moores Cancer Center, La Jolla, CA 92037, USA
74Department of Urology, Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands
75Clinical Gerontology Unit, University of Cambridge, Cambridge, CB2 2QQ, UK
76Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA
77George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah 84148, USA
78The University of Surrey, Guildford, Surrey, GU2 7XH
79Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
80Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
81Department of Epidemiology and Biostatistics, School of Public Health, Imperial
College London, SW7 2AZ, UK
Table S1. Contributing studies. Descriptions of PRACTICAL study groups that contributed data towards this analysis. The number of cases and controls provided by each study group is also listed.

<table>
<thead>
<tr>
<th>Study Group Acronym</th>
<th>Study Group Name</th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>BioVU</td>
<td>Vanderbilt University</td>
<td>204</td>
<td>0</td>
</tr>
<tr>
<td>CPDR</td>
<td>Uniformed Services University-Center for Prostate Disease Research</td>
<td>135</td>
<td>41</td>
</tr>
<tr>
<td>CeRePP</td>
<td>French Prostate Case-Control Study</td>
<td>101</td>
<td>84</td>
</tr>
<tr>
<td>EPICAP</td>
<td>EPIdemiology of Prostate CAncer</td>
<td>20</td>
<td>9</td>
</tr>
<tr>
<td>KARU PROSTATE</td>
<td>French West Indies Prostate cancer Study</td>
<td>363</td>
<td>386</td>
</tr>
<tr>
<td>MIAMI-WFPCS</td>
<td>The University of Miami – Sylvester Comprehensive Cancer Center</td>
<td>59</td>
<td>49</td>
</tr>
<tr>
<td>MOFFITT</td>
<td>The Moffitt Group</td>
<td>101</td>
<td>91</td>
</tr>
<tr>
<td>NMHS</td>
<td>Nashville Men’s Health Study</td>
<td>176</td>
<td>188</td>
</tr>
<tr>
<td>PCaP</td>
<td>North Carolina – Louisiana Prostate Cancer Project Consortium</td>
<td>967</td>
<td>0</td>
</tr>
<tr>
<td>PROtEuS</td>
<td>Prostate Cancer and Environment Study</td>
<td>70</td>
<td>53</td>
</tr>
<tr>
<td>SABOR</td>
<td>San Antonio Center of Biomarkers of Risk for Prostate Cancer</td>
<td>105</td>
<td>106</td>
</tr>
<tr>
<td>SCCS</td>
<td>Southern Community Cohort Study</td>
<td>291</td>
<td>1498</td>
</tr>
<tr>
<td>SCPCS</td>
<td>South Carolina Prostate Cancer Study</td>
<td>57</td>
<td>32</td>
</tr>
<tr>
<td>SFPCS</td>
<td>San Francisco Bay Area Prostate Cancer Study</td>
<td>81</td>
<td>36</td>
</tr>
<tr>
<td>SWOG-PCPT</td>
<td>Prostate Cancer Prevention Trial</td>
<td>43</td>
<td>121</td>
</tr>
<tr>
<td>SWOG-SELECT</td>
<td>Selenium and Vitamin E Cancer Prevention Trial</td>
<td>30</td>
<td>167</td>
</tr>
<tr>
<td>UKGPCS</td>
<td>U.K. Genetic Prostate Cancer Study and The Prostate Cancer Research Foundation Study</td>
<td>365</td>
<td>0</td>
</tr>
<tr>
<td>WUGS</td>
<td>Washington University Genetics Study</td>
<td>72</td>
<td>152</td>
</tr>
</tbody>
</table>
Table S2. Permutation performance. Mean and 95% confidence intervals for performance metrics estimated for each permutation of the cross-validation procedure.

<table>
<thead>
<tr>
<th>metric</th>
<th>Any prostate cancer</th>
<th>Aggressive prostate cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR20/50</td>
<td>0.53 [0.51-0.54]</td>
<td>0.51 [0.50-0.53]</td>
</tr>
<tr>
<td>HR80/20</td>
<td>4.07 [3.81-4.32]</td>
<td>4.42 [4.09-4.77]</td>
</tr>
<tr>
<td>HR98/50</td>
<td>3.49 [3.29-3.69]</td>
<td>3.77 [3.50-4.04]</td>
</tr>
</tbody>
</table>
Table S3. Results of SNP-scan. Description of 12 SNPs identified in 100 permutations of cross-validation SNP-scan. The position of each SNP is based on version 37. The count is the number of times the SNP appeared in permutations.

<table>
<thead>
<tr>
<th>RS number</th>
<th>Chromosome</th>
<th>Effect</th>
<th>Reference</th>
<th>Position</th>
<th>count</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs76229939</td>
<td>8</td>
<td>G</td>
<td>A</td>
<td>128085394</td>
<td>87</td>
</tr>
<tr>
<td>rs74421890</td>
<td>8</td>
<td>A</td>
<td>G</td>
<td>128096183</td>
<td>87</td>
</tr>
<tr>
<td>rs5013678</td>
<td>8</td>
<td>G</td>
<td>A</td>
<td>128103979</td>
<td>54</td>
</tr>
<tr>
<td>rs144732329</td>
<td>2</td>
<td>C</td>
<td>A</td>
<td>20130787</td>
<td>18</td>
</tr>
<tr>
<td>rs76595456</td>
<td>8</td>
<td>A</td>
<td>G</td>
<td>128087829</td>
<td>13</td>
</tr>
<tr>
<td>rs339353</td>
<td>6</td>
<td>A</td>
<td>C</td>
<td>117202475</td>
<td>8</td>
</tr>
<tr>
<td>rs1456315</td>
<td>8</td>
<td>A</td>
<td>G</td>
<td>128103937</td>
<td>6</td>
</tr>
<tr>
<td>rs184167671</td>
<td>17</td>
<td>G</td>
<td>A</td>
<td>54159621</td>
<td>5</td>
</tr>
<tr>
<td>rs339359</td>
<td>6</td>
<td>A</td>
<td>G</td>
<td>117160693</td>
<td>3</td>
</tr>
<tr>
<td>rs610424</td>
<td>6</td>
<td>G</td>
<td>A</td>
<td>117212258</td>
<td>1</td>
</tr>
<tr>
<td>rs339302</td>
<td>6</td>
<td>T</td>
<td>A</td>
<td>117224641</td>
<td>1</td>
</tr>
<tr>
<td>rs6983561</td>
<td>8</td>
<td>C</td>
<td>A</td>
<td>128106880</td>
<td>1</td>
</tr>
</tbody>
</table>
**Table S4.** SNP correlation matrix. Pearson correlation coefficient matrix of three SNPs selected for addition to the PHS46+African model.

<table>
<thead>
<tr>
<th>RS number</th>
<th>rs76229939</th>
<th>rs74421890</th>
<th>rs5013678</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs76229939</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs74421890</td>
<td>-0.0520</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>rs5013678</td>
<td>-0.0646</td>
<td>-0.0759</td>
<td>1</td>
</tr>
<tr>
<td>Threshold</td>
<td>Value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20\textsuperscript{th} percentile</td>
<td>-0.58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30\textsuperscript{th} percentile</td>
<td>-0.47</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70\textsuperscript{th} percentile</td>
<td>-0.13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80\textsuperscript{th} percentile</td>
<td>-0.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>98\textsuperscript{th} percentile</td>
<td>0.39</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table S6. Mean PHS46+African scores. Mean PHS46+African risk scores are tabulated for all individuals, cases, and controls in the African dataset.

<table>
<thead>
<tr>
<th></th>
<th>Mean [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>-0.22 [-0.23,-0.21]</td>
</tr>
<tr>
<td>Cases</td>
<td>-0.16[-0.17,-0.14]</td>
</tr>
<tr>
<td>Controls</td>
<td>-0.29[-0.30,-0.28]</td>
</tr>
</tbody>
</table>